| Title |
Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, March 2008
|
| DOI | 10.1007/s00280-008-0711-0 |
| Pubmed ID | |
| Authors |
Vincent Launay-Vacher, Jean-Baptiste Rey, Corinne Isnard-Bagnis, Gilbert Deray, Mikael Daouphars |
| Abstract |
Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP). |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 11% |
| India | 1 | 11% |
| Unknown | 7 | 78% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 56% |
| Practitioners (doctors, other healthcare professionals) | 3 | 33% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 125 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| France | 1 | <1% |
| Unknown | 123 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 19 | 15% |
| Student > Master | 17 | 14% |
| Researcher | 16 | 13% |
| Other | 13 | 10% |
| Student > Doctoral Student | 9 | 7% |
| Other | 29 | 23% |
| Unknown | 22 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 43 | 34% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 15% |
| Agricultural and Biological Sciences | 11 | 9% |
| Chemistry | 9 | 7% |
| Biochemistry, Genetics and Molecular Biology | 7 | 6% |
| Other | 10 | 8% |
| Unknown | 26 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 October 2019.
All research outputs
#2,332,804
of 25,401,784 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#52
of 2,563 outputs
Outputs of similar age
#6,376
of 95,772 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#2
of 25 outputs
Altmetric has tracked 25,401,784 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,563 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,772 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.